
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Adult T-cell leukemia future or investigational therapies
Introduction
Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.[1][2][3]
- ↑ Litzow MR, Ferrando AA (August 2015). “How I treat T-cell acute lymphoblastic leukemia in adults”. Blood. 126 (7): 833–41. doi:10.1182/blood-2014-10-551895. PMID 25966987.
- ↑ Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J (November 2014). “JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model”. Blood. 124 (20): 3092–100. doi:10.1182/blood-2014-04-566687. PMID 25193870.
- ↑ Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG (April 2012). “Targeting nonclassical oncogenes for therapy in T-ALL”. Cancer Cell. 21 (4): 459–72. doi:10.1016/j.ccr.2012.02.029. PMID 22516257.
